Acrux

Acrux Accounts Payable

The Accounts Payable of Acrux (ACR.AX) as of Oct 10, 2026 is 728,000.00 AUD. In the previous year, Accounts Payable was 463,000.00 AUD — a change of 57.24% (higher).

Accounts Payable

728,000.00AUD

YoY

57.24%

Last updated:

Accounts Payable of Acrux is 2026 728,000.00 AUD. Accounts Payable of Acrux was 2025 463,000.00 AUD. It decreases by 57.24% higher compared to the previous year.

The Acrux Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
901,000.00 AUD
Jan 1, 2020
1.03 M AUD
Jan 1, 2021
312,000.00 AUD
Jan 1, 2022
789,000.00 AUD
Jan 1, 2023
488,000.00 AUD
Jan 1, 2024
427,000.00 AUD
Jan 1, 2025
463,000.00 AUD
Jan 1, 2026
728,000.00 AUD
The Acrux Accounts Payable history
YEARAccounts PayableYoY
728,000.00AUD+57.24%
463,000.00AUD+8.43%
427,000.00AUD-12.50%
488,000.00AUD-38.15%
789,000.00AUD+152.88%
312,000.00AUD-69.56%
1.03 MAUD+13.76%
901,000.00AUD+23.26%
731,000.00AUD+29.61%
564,000.00AUD-6.93%
606,000.00AUD+471.70%
106,000.00AUD-51.15%
217,000.00AUD—
Access this data via the Eulerpool API

Acrux Stock analysis

What does Acrux do? Acrux Ltd is an Australian pharmaceutical company specializing in the development and marketing of products in the dermatology field. The company was founded in 1998 and is headquartered in Melbourne. Its history begins with the development of a groundbreaking technology called the "Sprayform® Technology," which allows the administration of liquid medications in spray form, providing numerous advantages compared to traditional administration methods. Acrux obtained the first patent for this technology in 1999 and worked on bringing it to the market. Its business model focuses on licensing its Sprayform® Technology to third parties to advance the development and marketing of products in various therapeutic areas. The company has an experienced research and development team that collaborates closely with partners to develop tailored solutions and support the entire development process, ensuring that all products meet the highest quality standards and regulatory requirements. Acrux Ltd is divided into various divisions, including products for women, diabetes, pain and inflammation, as well as neurology and psychiatry. With its Sprayform® Technology, the company has developed unique therapeutic solutions that meet patients' needs. For example, a testosterone preparation for women has been developed that is simply applied as a spray and offers higher efficacy than traditional tablets. Another product is a fast-acting pain reliever that is administered through a nasal spray. Acrux Ltd also has partnerships with major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, Pfizer, and Sanofi. These partnerships enable Acrux to market its technology globally and offer its customers a comprehensive portfolio of tailored solutions. The partner is granted exclusive rights to use the technology for specific products and markets, facilitating the development of new products and the expansion into new regions. Overall, Acrux Ltd has achieved a leadership position in the field of transdermal systems and transmucosal technologies through its innovative Sprayform® Technology. The company aims to further expand its leadership position by focusing on the development of new products and collaboration with partners. Acrux remains in constant exchange with the scientific community to incorporate the latest research and development insights into its products. Acrux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrux stock

Accounts Payable of Acrux is 728,000.00 AUD in 2026.

Accounts Payable of Acrux changed from 463,000.00 AUD to 728,000.00 AUD, representing a 57.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Acrux since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Acrux historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Acrux

All Key Metrics — Acrux